Hepatitis C has become the real protagonist of Spanish health for a few months, as a result of the protests initiated by patients (with enclosures in hospitals included).
TG4040 is a modified Ankara vaccine virus that expresses the hepatitis C virus NS3, NS4 and NS5B proteins (therapeutic vaccine). The Foundation participated in a phase II clinical trial in patients with chronic hepatitis C.
En agosto la revista New England Journal of Medicine publica un artículo sobre el tratamiento libre de interferón de la hepatitis crónica C con Faldaprevir (inhibidor de la proteasa del virus) y Deleobuvir (inhibidor de la polimerasa vírica).